Brokerage Firm Rating Update on Dynavax Technologies Corporation (DVAX)

Dynavax Technologies Corporation (DVAX) : The consensus on Dynavax Technologies Corporation (DVAX) based on 3 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Dynavax Technologies Corporation (DVAX) : The consensus price target for Dynavax Technologies Corporation (DVAX) is $35.67 for the short term with a standard deviation of $16.17. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $45, however, the pessimist price target for the company is $17.


For the current week, the company shares have a recommendation consensus of Buy.

Dynavax Technologies Corporation (NASDAQ:DVAX): stock was range-bound between the intraday low of $12.53 and the intraday high of $14.1 after having opened at $13.98 on Wednesdays session. The stock finally closed in the red at $13.98, a loss of -8.14%. The stock remained in the red for the whole trading day. The total traded volume was 4,505,565 shares. The stock failed to cross $14.1 in Wednesdays trading. The stocks closing price on Thursday was $14.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.